How often do you update the AIMT stock price projections?
"AIMT" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Q&A about "AIMT" projections. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Aimmune Therapeutics Inc.
Is AIMT a good stock to buy according to hedge funds?
Aimmune Therapeutics Inc (NASDAQ:AIMT) is not the least popular stock in this group but hedge fund interest is still below average. This is a slightly negative signal and we'd rather spend our time researching stocks that hedge funds are piling on.
What is aimmune Therapeutics'stock price?
Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT." What is Aimmune Therapeutics' stock price today? One share of AIMT stock can currently be purchased for approximately $34.49.
What will the AIMT price be in 14 days?
to get chart pattern analyze. AIMT price target in 14 days: 34.799 USD* upside and 34.496 USD* downside. (Highest and lowest possible predicted price in a 14 day period) Get Our PREMIUM Forecast Now, from ONLY $8.49!
How were Aimmune Therapeutics' earnings last quarter?
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) posted its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported ($1.06) ear...
Who are Aimmune Therapeutics' key executives?
Aimmune Therapeutics' management team includes the following people: Dr. Jayson Donald Alexander Dallas , Pres, CEO & Director (Age 51) Mr. Eric...
Who are some of Aimmune Therapeutics' key competitors?
Some companies that are related to Aimmune Therapeutics include Organon & Co. (OGN) , Grifols (GRFS) , Maravai LifeSciences (MRVI) , Legend Bio...
What other stocks do shareholders of Aimmune Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN)...
When did Aimmune Therapeutics IPO?
(AIMT) raised $124 million in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14....
What is Aimmune Therapeutics' stock symbol?
Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."
What is Aimmune Therapeutics' stock price today?
One share of AIMT stock can currently be purchased for approximately $34.49.
How much money does Aimmune Therapeutics make?
Aimmune Therapeutics (NASDAQ:AIMT) has a market capitalization of $2.26 billion. The biotechnology company earns $-248.50 million in net income (pr...
How many employees does Aimmune Therapeutics have?
Aimmune Therapeutics employs 228 workers across the globe.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of desensitization treatments for peanut and other food allergies. Its Characterized Oral Desensitization Immunotherapy includes AR101, a product in Phase 3 registration trial for the treatment of peanut allergy in children and adults.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
AIMT Target Price
AIMT price target in 14 days: 34.799 USD* upside and 34.496 USD* downside. (Highest and lowest possible predicted price in a 14 day period)
Aimmune Therapeutics Inc ( AIMT ) Stock Market info
Recommendations: Buy or sell Aimmune Therapeutics stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Aimmune Therapeutics share forecasts, stock quote and buy / sell signals below.
Summary
After Palforzia received the 7-2 votes for approval by the advisory committee, the stock didn't rally immediately.
About The Company
As usual, I'll present a brief corporate overview for new investors. If you are familiar with the firm, I suggest that you skip to the subsequent section. Headquartered in Brisbane, California, Aimmune Therapeutics is engaged in the innovation and commercialization of medicines to serve the strong unmet needs in food allergy.
Pipeline Strategy
As an oral medicine to treat peanut allergy, Palforzia is the first of its kind. In other words, Palforzia is a powerful preventative (i.e. prophylactic) therapy to treat the highly common and devastating condition, peanut allergy. I believe that Palforzia is special because it is innovated by Aimmune's CODIT technology.
Expert Recommendation
On September 13 this year, the Advisory Committee (ADCOM) voted 7 to 2 in favor of Palforzia approval for children and teens. Using probability analysis (another form of higher-level intelligence), I correctly foresaw the outcome of the votes in advance. But I was quite intrigued during my live coverage of the meeting for IBI members.
Palforzia's Upcoming Launch
Asides from the FDA, Aimmune is advancing Palforzia for patients in Europe. Back in June, the company submitted its marketing application authorization with the EMA. On the 12 to 15 months' standard review in Europe, I expect approval to come in 3Q2020.
Market Potential
Shifting gears, you should check Palforzia's market potential. In my recent blog, I shared some secrets to finding stocks that are likely to rally (i.e. a high probability event). One such secret is to pick only companies with a drug having strong market potential (i.e. a blockbuster niche).
Financials Assessment
Just as you would get an annual physical for your well-being, it's important to check the financial health of your stock. For instance, your health is affected by "blood flow" as your stock's viability is dependent on the "cash flow." With that in mind, I'll analyze the 3Q2019 earnings report for the period that ended on September 30.
